Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
6.60
+0.01 (0.15%)
At close: May 12, 2025, 4:00 PM
6.54
-0.06 (-0.91%)
After-hours: May 12, 2025, 7:57 PM EDT
Wave Life Sciences Revenue
Wave Life Sciences had revenue of $9.18M in the quarter ending March 31, 2025, a decrease of -26.82%. This brings the company's revenue in the last twelve months to $104.94M, down -7.06% year-over-year. In the year 2024, Wave Life Sciences had annual revenue of $108.30M, down -4.42%.
Revenue (ttm)
$104.94M
Revenue Growth
-7.06%
P/S Ratio
9.22
Revenue / Employee
$364,372
Employees
288
Market Cap
1.02B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 108.30M | -5.00M | -4.42% |
Dec 31, 2023 | 113.31M | 109.66M | 3,005.10% |
Dec 31, 2022 | 3.65M | -37.32M | -91.09% |
Dec 31, 2021 | 40.96M | 20.89M | 104.03% |
Dec 31, 2020 | 20.08M | 4.09M | 25.61% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
WVE News
- 3 days ago - Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 11 days ago - Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025 - GlobeNewsWire
- 6 weeks ago - Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531 - Seeking Alpha
- 6 weeks ago - Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year - Benzinga
- 6 weeks ago - Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531 - GlobeNewsWire
- 2 months ago - Wave Life Sciences Ltd. (WVE) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire